clinically isolated syndrome

People who experience a first attack of multiple sclerosis (MS)-like disease are less likely to experience long-term disability progression if they start  treatment within the first few months, a new study reports. “When it comes to MS treatment, the earlier the better,” Alvaro Cobo-Calvo, MD, PhD, co-author of the…

In 2007, at age 47, I had my first-ever consultation with a neurologist. It was during my longest-ever hospital stay, as of then — a whopping eight days. It amazed me that some of my fellow patients in the ward managed to gather themselves and struggle outside for a ciggy,…

“Most of the time, the greatest rewards come from doing the things that scare you the most. Maybe you’ll get everything you wish for. Maybe you’ll get more than you ever could have imagined. Who knows where life will take you? The road is long, and in the end, the…

Paramagnetic rim lesions, a specific form of inflammatory damage to the brain, are rarely found in people with disorders other than multiple sclerosis (MS), according to a study in adults with suspected MS. Its findings suggest that looking at PRLs could be useful for diagnosing the disease. Brain Renner,…

Lower-than-normal volumes of certain brain regions at disease onset — indicating shrinkage, or atrophy, in those regions — are significantly associated with current and future fatigue severity in people with multiple sclerosis (MS), a study in Germany shows. Some of these regions also were found to be central brain…

Combined Data May Predict Person’s Risk of Advancing From CIS to MS Clinically isolated syndrome is sometimes called “early MS.” It’s the diagnosis used when someone’s symptoms don’t quite look like MS, but it does appear that MS is lurking. It may take years for an actual…

A novel algorithm that combines genetic, environmental, and clinical data could be useful for predicting whether people with a first onset of multiple sclerosis (MS)-like disease — known as clinically isolated syndrome (CIS) — will experience relapses or a worsening of their disease over time. The…

Mavenclad (cladribine) reduces the number and volume of lesions in patients at risk of multiple sclerosis (MS) after a first clinical demyelinating event, a study based on Phase 3 trial data found. A demyelinating event occurs when myelin — the protective coating around nerve fibers — experiences damage; this…

After a pregnancy or childbirth, most women who went on to develop clinically isolated syndrome (CIS) did so about three years later than those who were never pregnant, a large and multicenter study reported. Multiple pregnancies or births, however, were not seen to further affect CIS onset. More research is…

A “prudent” diet rich in fresh fruit, non-fried fish, whole grains, vegetables, and nuts may lower the likelihood of a relapse in people with a first demyelinating event, a major risk factor for multiple sclerosis (MS), a study in Australia suggests. While the researchers did not find a strong link…

Mavenclad (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple sclerosis (MS) for at least five years after the last dose, according to a real-life study from Italy. These findings, based on real-world data from Italian MS patients previously treated…

Supporting evidence that infection with Epstein-Barr virus (EBV) could be one of the root causes of multiple sclerosis (MS), a recent study found all of its 901 early disease patients carry antibodies against this virus, meaning that all are or have been exposed to it. The study, “…

A blood-cleansing process known as immunoadsorption appears to be superior to plasma exchange in treating relapses that don’t respond to conventional steroid therapy in people with multiple sclerosis (MS) or clinically isolated syndrome (CIS), a study reports. These findings were reported in “Safety and efficacy of immunoadsorption…

Using newer disease-modifying therapies (DMTs) as an initial treatment for children and adolescents with multiple sclerosis (MS) or clinically isolated syndrome (CIS) is associated with fewer relapses and brain lesions compared to the use of older and injectable DMTs, according to a real-world study in the U.S.

Imaging techniques that measure damage to the brain, in addition to those that detect lesions, may be useful in predicting likely disease progression in people with clinically isolated syndrome (CIS), a study found. The study, “Early imaging predictors of longer term multiple sclerosis risk and severity…

The percentage of Taiwanese who develop multiple sclerosis (MS) after an episode of clinically isolated syndrome (CIS) is lower than that reported for other ethnicities, and those who do progress are likely to have a milder disease course, a study found, supporting how factors like geography and genetics…

A woman’s age at her first menstruation, or becoming pregnant and breastfeeding does not substantially influence the long-term risk of multiple sclerosis (MS) or the risk of increased disability, a study of a large number of patients with clinically isolated syndrome…

The “regulatory environment” favored Mayzent (siponimod) being approved as an oral treatment for people with relapsing multiple sclerosis (MS) — specifically, clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive MS (SPMS) — a top executive with Novartis said, although the pharmaceutical company had requested a label covering all with SPMS. Dan…

National organizations that represent patients with multiple sclerosis (MS) welcome the U.S. Food and Drug Administration’s March 26 approval of Novartis’ oral therapy Mayzent (siponimod) — but they complain that, at $88,500 per year, the treatment is overpriced. The Multiple Sclerosis Society of America (MSSA) is clearly upbeat about the…

Lesions in the infratentorial region of the brain at the onset of clinically isolated syndrome (CIS) and lesions in white matter one year after CIS onset are associated with worse disability 30 years later, a study reports. The study, “Early MRI predictors of long-term multiple sclerosis outcomes:…

The number, location, and size of lesions can help predict the risk of progression from clinically isolated syndrome (CIS) to multiple sclerosis (MS) within one year, a new study shows. The study, “MRI in predicting conversion to multiple sclerosis within 1 year,” was published in the journal…

Higher-than-usual levels of specific antibodies in the blood of patients with clinically isolated syndrome (CIS) may predict a faster progression to multiple sclerosis (MS), an Australian study reports. The specific antibody is known as IgG3, an immunoglobulin known to promote inflammation. The study, “Higher Serum Immunoglobulin G3 Levels May Predict…

Changes in the brains of patients with clinically isolated syndrome (CIS), the first clinical presentation of multiple sclerosis (MS), may be partly responsible for depressive symptoms and reduced quality of life in these patients, a study shows. The study with that finding, “Health-related quality of life, neuropsychiatric…

B-cell alterations in peripheral blood may predict the conversion of clinically isolated syndrome (CIS) to multiple sclerosis (MS), a recent study suggests. Conducted in Turkey, the study, “Peripheral blood memory B cell frequency predicts conversion from clinically isolated syndrome to multiple sclerosis,” was published in…

After the first round of symptoms, multiple sclerosis can stay mild without causing major problems for decades, a 30-year British study indicates. Karen K. Chung of the University College London Institute of Neurology discussed the findings at the ECTRIMS-ACTRIMS meeting in Paris, which started Oct. 25 and runs until 28. His presentation was titled “Does…

The types of brain and spinal cord inflammation patches that occur in a precursor condition to multiple sclerosis help determine whether a person develops MS in the next 15 years, a British neurologist reported today. Wallace J. Brownlee of the University College London Institute of Neurology made the observation in…

Women who breastfeed for 15 months or longer may have a lower risk of developing multiple sclerosis (MS) than those who breastfeed for shorter periods or not at all, according to a recent study. The study also suggests that women who had their first…

Eating a diet high in salt won’t worsen or speed up multiple sclerosis (MS) symptoms, concludes a study of MS patients with clinically isolated syndrome (CIS). That contradicts earlier studies by researchers from Argentina, Vermont and elsewhere who warned of a possible link between high sodium consumption and MS. The…

A common acne medicine called minocycline can reduce the rate of multiple sclerosis progression in patients who are at early stages of the disease, according to a Phase 3 clinical trial. The finding was from the MinoCIS trial (NCT00666887) of minocycline, which goes by the brand name Mynocan and other…

Multiple sclerosis (MS) patients with more advanced disease, as evidenced by disability, and those more frequent relapses or aversion to needles are among the groups of people at higher risk of discontinuing Betaferon (interferon beta-1b) treatment, researchers report. These findings may help to alert clinicians to those least likely to adhere to…